Special Issue

Targeted Drug Delivery in Immune Diseases

Message from the Guest Editors

Autoimmune and neurodevelopmental diseases have been treated using therapies that suppress systemic immune responses, which can result in significant side effects. Alternatively, immune tolerance induction through antigen-specific treatments can inhibit disease-associated responses without systemic suppression. Previously, immune tolerance has been accomplished via soluble antigen delivery through oral, nasal, or sublingual routes. However, these therapies have shown minimal success in clinical settings. Multiple sclerosis (MS) is a neurodegenerative condition. Though several treatments have been developed to protect nerves, a comprehensive improvement in MS is still considered an essential bottleneck. Autism spectrum disorder (ASD) is characterized by high heritability and clinical heterogeneity. No medications are approved for treating these symptoms, and medicines used to treat non-specific symptoms have serious side effects. Rheumatoid arthritis (RA) is a chronic inflammatory disease. Today, nanotechnology has emerged as a promising tool in developing novel drug delivery systems for treating and diagnosing intractable diseases such as RA.

Guest Editors

Prof. Dr. Sheikh Fayaz Ahmad

Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia

Prof. Dr. Ahmed Nadeem

Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia

Deadline for manuscript submissions

closed (15 December 2023)

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/si/159753

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/journal/biomedicines

MDPI

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).